comprehensive -WSS

comprehensive

author：hotspot 2025-09-06 08:25:09 - browse：7933

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： For BCIs, commercial hurdles may be bigger than scientific ones

leisure time

Wikipedia

WSS

A strong 6.5

What Henrietta Lacks settlement says about racism in medicine

'Ancient DNA,' 23andMe reveal African American ancestries

Manchin plays down potential 3rd

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

US soldier in North Korean custody after crossing DMZ line

knowledge

comprehensive

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

A strong 6.5

Affirmative action in medical school literally saved lives

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

How to save PrEP access — and even expand it

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Alkermes shareholders re

Microsoft strikes partnership with Duke Health to advance health AI

Hollywood unions extend contract negotiations for actors

Johnson & Johnson sues to stop Medicare negotiation

focus

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

White House drug shortage group privately met with industry

Dramatically reducing cancer deaths requires the PASTEUR Act

Robert Kennedy Jr.'s presidential campaign attracts GOP

Humana, CVS hope to turn members into patients at clinics

US soldier in North Korean custody after crossing DMZ line

leisure time

Wikipedia

leisure time

entertainment